Archive: February 2018

The Development of Endoxifen for Breast Cancer

Matthew P. Goetz, MD

  H&O  Could you please describe how tamoxifen works, and its history as a treatment for breast cancer? MG  Tamoxifen is a selective estrogen receptor modulator […]

How We Treat Brain Metastases in Metastatic Renal Cell Carcinoma

Sundhar Ramalingam, MD, Daniel J. George, MD, and Michael R. Harrison, MD

  Overview • Brain metastasis in patients with metastatic renal cell carcinoma generally signifies a poor prognosis. • Surgical resection is an option for patients with […]

Advances in CAR T-Cell Therapy for Chronic Lymphocytic Leukemia

David L. Porter, MD

  H&O  How does CAR T-cell therapy work? DP  A patient’s T cells are removed through leukapheresis and then genetically modified in the laboratory so that […]

Myelofibrosis: Clinicopathologic Features, Prognosis, and Management 

Jennifer M. O’Sullivan, MD, MRCP, FRCPath, and Claire N. Harrison, MD, FRCP, FRCPath

  Abstract: Myelofibrosis is one of the BCR-ABL–negative clonal disorders that collectively are known as myeloproliferative neoplasms (MPNs). It is caused by the proliferation of clonal […]

Management of Acute Lymphoblastic Leukemia in Young Adults

Lori S. Muffly, MD, MS, Natalie Reizine, MD, and Wendy Stock, MD

  Abstract:  Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that […]

Current and Emerging First-Line Systemic Therapies in Clear Cell Renal Cell Carcinoma

Brian I. Rini, MD

  H&O  Which patients with clear cell renal cell carcinoma (RCC) are candidates for systemic therapy? BR  All patients with clear cell RCC are potential candidates […]

Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma

Cabozantinib (Cabometyx, Exelixis) received an expanded indication from the US Food and Drug Administration (FDA) on December 19 as a first-line treatment in patients with advanced […]

How to Manage Patients With Moderate-Risk Germline Mutations 

Nadine M. Tung, MD

  H&O  Which germline mutations are associated with a high risk for breast cancer? NT  Mutations in BRCA1 and BRCA2, TP53, PTEN, CDH1, and STK11 are considered […]

Back to Archive